Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Aripiprazole
Drug ID BADD_D00165
Description Aripiprazole is an atypical antipsychotic orally indicated for treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's[Label]. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania[Label]. Aripiprazole exerts its effects through agonism of dopaminic and 5-HT1A receptors and antagonism of alpha adrenergic and 5-HT2A receptors[Label,A4393]. Aripiprazole was given FDA approval on November 15, 2002[L6136].
Indications and Usage Aripiprazole is indicated for manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, treatment of schizophrenia, treatment of Tourette's disorder, and as an adjunctive treatment of major depressive disorder[Label]. An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania[Label].
Marketing Status approved; investigational
ATC Code N05AX12
DrugBank ID DB01238
KEGG ID D01164
MeSH ID D000068180
PubChem ID 60795
TTD Drug ID D0H3HM
NDC Product Code 82009-090; 12658-0524; 46602-0009; 46602-0102; 46602-1030; 46602-1032; 49706-1889; 13668-219; 16729-279; 16729-280; 29300-176; 29300-179; 31722-820; 31722-829; 33342-126; 43547-302; 43598-969; 46708-260; 59148-031; 59148-033; 59148-114; 60505-2677; 60687-157; 65162-896; 65162-898; 67877-431; 68071-2705; 68382-083; 70518-3692; 71335-1515; 71335-1893; 72865-156; 76483-103; 82009-091; 0904-6512; 46602-1034; 53747-031; 65691-0052; 65841-140; 65862-680; 68554-0020; 13668-217; 27241-051; 31722-819; 31722-920; 31722-921; 43353-147; 43353-148; 43547-305; 48433-115; 48433-119; 50228-478; 59148-006; 59148-011; 59148-034; 59148-102; 60505-2674; 65162-899; 65862-664; 65862-666; 67877-435; 68382-439; 69452-339; 70518-2643; 70518-2736; 70518-2820; 70518-2869; 70771-1451; 72578-106; 76483-102; 0904-6656; 46602-0026; 65372-1121; 65862-661; 65862-663; 69037-0058; 27241-052; 27241-053; 27241-054; 31722-830; 33342-125; 48433-117; 50090-4800; 50268-091; 50268-092; 59148-009; 59148-019; 60687-168; 62332-097; 65162-893; 65162-897; 68788-7808; 70518-2515; 70518-2557; 70518-2825; 70518-2974; 70518-3090; 70771-1452; 71335-1832; 71428-018; 72189-476; 53808-1101; 59148-007; 59148-010; 59148-045; 60505-2673; 63739-074; 63739-078; 63739-413; 65162-902; 65862-662; 67877-434; 70518-2508; 70518-2584; 71205-392; 71335-1903; 72865-182; 72865-185; 76483-100; 0904-6511; 0904-6513; 46602-1029; 63415-0085; 13668-220; 16714-142; 16729-282; 16729-283; 43598-559; 43598-966; 46708-257; 46708-258; 50090-3941; 50090-4665; 50090-6563; 50228-326; 59148-008; 60505-2675; 60687-191; 60687-202; 60687-213; 62332-101; 63187-965; 63629-7774; 63739-069; 68382-084; 70518-2536; 70771-1454; 71205-480; 71335-1980; 72189-455; 72189-456; 72865-157; 72865-180; 82009-089; 12658-0602; 46602-1031; 50370-0009; 53104-7628; 13668-216; 16714-145; 29300-178; 43598-556; 43598-968; 46708-261; 50228-476; 50228-477; 50268-089; 50268-090; 59148-018; 59148-032; 60505-2676; 60505-3075; 62332-098; 62332-103; 65162-901; 67877-433; 70518-2827; 0615-8375; 72865-183; 76282-044; 76282-045; 76483-101; 12658-0599; 12828-0088; 46602-0006; 46602-0025; 58032-2005; 72761-020; 13668-221; 16714-143; 16729-278; 16729-281; 27241-055; 31722-919; 31722-922; 31722-924; 43598-557; 46708-259; 48433-120; 59148-029; 59651-110; 62332-102; 68382-085; 68788-7006; 68788-7063; 68788-7733; 68788-7749; 68788-8089; 70518-0970; 70518-2580; 70518-2958; 70771-1455; 72865-153; 72865-155; 72865-181; 82009-088; 0904-6510; 12658-0577; 46602-1033; 50370-0044; 50370-0055; 29300-175; 29300-180; 43547-303; 43547-304; 43598-554; 43598-965; 43598-970; 46708-255; 50090-6063; 50228-325; 50228-475; 60505-0404; 65862-665; 69452-338; 70518-2567; 70771-1453; 70771-1456; 71335-1513; 72865-184; 76282-048; 0904-6514; 12658-0542; 46602-0010; 46602-0072; 58623-0127; 65096-0107; 16714-146; 33342-122; 33342-127; 43353-140; 43547-306; 43598-967; 46708-256; 48433-116; 50090-6403; 60687-179; 62332-099; 63739-070; 66689-735; 67877-430; 67877-432; 68382-086; 70518-1295; 70518-2806; 70518-2950; 71335-1682; 71335-1892; 72578-107; 72865-154; 72888-100; 76282-047; 76282-049; 46602-0007; 46602-0008; 46602-0045; 46602-0114; 59116-2900; 59116-2901; 67835-0009; 68554-0095; 76072-1002; 13668-218; 29300-177; 31722-828; 33342-123; 33342-124; 43547-307; 46708-254; 50228-329; 50268-088; 54838-570; 62332-100; 62332-104; 63629-7108; 68071-2676; 68071-2708; 68382-082; 70518-2765; 70518-2897; 70518-2921; 70518-3380; 71335-1687; 71335-1935; 72189-466; 72865-158; 76282-046; 0904-6509; 12658-0576; 12658-0601; 14445-019; 46602-0011; 64220-112; 16714-141; 16714-144; 16714-785; 27241-056; 31722-827; 31722-923; 43353-180; 43598-555; 43598-558; 48433-118; 50090-5839; 50090-6409; 50228-324; 50228-327; 50228-328; 50228-479; 50228-480; 50268-087; 59148-030; 59148-072
UNII 82VFR53I78
Synonyms Aripiprazole | 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone | Aripiprazol | Abilify | OPC 14597 | OPC-14597
Chemical Information
Molecular Formula C23H27Cl2N3O2
CAS Registry Number 129722-12-9
SMILES C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Myositis15.05.01.0010.000119%
Narcolepsy17.15.01.002; 19.02.02.0020.000079%Not Available
Nasal congestion22.04.04.001--
Nasal dryness22.04.03.002--Not Available
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Neck pain15.03.04.009--
Necrosis24.04.02.006; 08.03.03.0010.000159%Not Available
Necrosis ischaemic24.04.02.0180.000079%Not Available
Neonatal disorder18.04.01.0010.000159%Not Available
Neoplasm16.16.02.001--Not Available
Nephrolithiasis20.04.01.002--
Nerve compression17.09.02.002; 12.01.12.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.0030.001070%Not Available
Neuralgia17.02.07.005--
Neurodermatitis23.03.04.0070.000079%Not Available
Neuroleptic malignant syndrome17.05.02.003; 15.05.04.015; 12.03.01.003; 08.05.01.0050.004478%Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neutropenia01.02.03.004--Not Available
Neutrophil count decreased13.01.06.010--
Neutrophil count increased13.01.06.011--Not Available
Night sweats23.02.03.006; 08.01.03.031--Not Available
Nightmare19.02.03.003--Not Available
Nocturia20.02.03.001--Not Available
Obesity14.03.02.0090.000515%
Obsessive thoughts19.06.05.0010.000079%Not Available
Obsessive-compulsive disorder19.06.05.0020.031020%Not Available
Ocular hyperaemia06.04.05.004--Not Available
Oculogyric crisis06.05.02.002; 17.01.03.0020.001189%Not Available
The 19th Page    First    Pre   19 20 21 22 23    Next   Last    Total 40 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene